August30, 2017 (C) Ravinder Singh firstname.lastname@example.org
It is shocking none of our News Media bothered to ascertain facts about ‘Patent Granted by Indian Patent Office in 113 days’ – after waiting for a fortnight I decided to DISCLOSE FACTS. No Exclusivity for this invention – 3 Original Patents and 121 Process Patents.
Ø Cadila India filed US Patent in 2014, filed in India recently & granted speedily. Its priority date is Nov25, 2014 – so at least 30 months or more.
Ø But it is Not Original Invention – it dates back to Sep21, 2001.
Ø Cadila merely filed a process
Apixapan at least 17 Yrs Old Invention – 121 Process Patents
Apixaban is the generic ingredient in one branded drug marketed by Bristol Myers Squibb and is included in one NDA. There are three patents protecting this compound and one Paragraph IV challenge. Additional information is available in the individual branded drug profile pages.
Apixaban has one hundred and twenty-one patent family members in forty countries.
There are twenty-four drug master file entries for apixaban. Two suppliers are listed for this compound.
I have attached Patent Ownership of few Important Apixaban Drug.
India has not yet learnt to ‘Create Original Inventions’ and Protecting & Commercialize them worldwide.
Ravinder Singh, Inventor & Consultant, INNOVATIVE TECHNOLOGIES AND PROJECTS
Y-77, Hauz Khas, ND -110016, India. Ph: 091- 9871056471, 9718280435, 9650421857